Skip to main content

Advertisement

SpringerLink
Log in

Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Some authors observed increased carboplatin-associated myelotoxicity in obese patients which was exclusively attributed to elevated AUC. To investigate the potential contribution of functional changes of cells primarily responsible for myelopoiesis, granulocyte–macrophage progenitors (CFU-GM) were studied in obesity-associated diabetes mellitus (DMT2).

Methods

The most frequently used animal model of human obesity with DMT2 is db/db mouse. Cellularity, frequency of CFU-GM and total CFU-GM content of femoral bone marrow were measured after 100 mg/kg dose of carboplatin in vivo. To exclude influence of pharmacokinetic changes, direct toxicity of carboplatin on CFU-GM was also determined in vitro and was compared with other anticancer agents, namely doxorubicin, 5-fluorouracil and 4-thiouridylate.

Results

After intraperitoneal administration of carboplatin, each measured characteristics of bone marrow function was more significantly suppressed and the induced neutropenia was more serious in db/db mice than in the controls. The increased myelotoxicity seemed to be a direct effect on myeloid progenitor cells since their increased in vitro sensitivity was found in db/db mice. This was not specific for carboplatin, a similar double to fivefold increase in myelotoxicity of each cytotoxic drug with different mechanism of action was observed. Four-thiouridylate, a promising antileukemic molecule with good therapeutic index, was by far the least toxic for CFU-GM of db/db mice.

Conclusions

A serious disorder of CFU-GM progenitors was suggested in obese mice with DMT2, which eventually might lead to more severe myelotoxicity and neutropenia. Weight loss and normalization of glucose homeostasis may be important before chemotherapy of malignant diseases in obesity with DMT2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ (2001) Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10:345–353

    CAS  PubMed  Google Scholar 

  2. Blouin RA, Warren GW (1999) Pharmacokinetic considerations in obesity. J Pharm Sci 88:1–7 Review

    Article  CAS  PubMed  Google Scholar 

  3. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL et al (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. American Society of Clinical Oncology. J Clin Oncol 30:1553–1561 Review

    Article  PubMed  Google Scholar 

  4. De Jonge ME, Mathot RA, Van Dam SM, Beijnen JH, Rodenhuis S (2002) Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 50:251–255

    Article  PubMed  Google Scholar 

  5. Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD (2009) Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol 64:115–122

    Article  CAS  PubMed  Google Scholar 

  6. Miyahara T, Mochinaga S, Kimura S, Aragane N, Yakabe T, Morita S, Okudaira K, Fujito H (2013) Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients. Cancer Chemother Pharmacol 71:175–182

    Article  CAS  PubMed  Google Scholar 

  7. Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M, Reaman GH, Scorsone K, Sung L, Dolan ME, Berg SL (2014) Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group. Cancer Chemother Pharmacol 74:831–838

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Fetting J, Davidson NE (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118:5937–5946

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E (2009) A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight and obese patients. Clin Cancer Res 15:3633–3639

    Article  CAS  PubMed  Google Scholar 

  10. Brown DL, Masselink AJ, Lalla CD (2013) Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation. Ann Pharmacother 47:1039–1044

    Article  PubMed  Google Scholar 

  11. Wright JD, Tian C, Mutch DG, Herzog TJ, Nagao S, Fujiwara K, Powell MA (2008) Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 109:353–358

    Article  CAS  PubMed  Google Scholar 

  12. Chen S, Chen CM, Zhou Y, Zhou RJ, Yu KD, Shao ZM (2012) Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. PLoS One 7:e41380. doi:10.137/journal.pone.0041380

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Au-Yeung G, Webb PM, DeFazio A, Fereday S, Bressl M, Mileshkin L (2014) Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol 133:16–22

    Article  CAS  PubMed  Google Scholar 

  14. Kashiwabara K, Yamane H, Tanaka H (2013) Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy. Cancer Invest 31:251–257

    Article  CAS  PubMed  Google Scholar 

  15. Géresi K, Benkő K, Szabó B, Megyeri A, Peitl B, Szilvássy Z, Benkő I (2012) Toxicity of cytotoxic agents to granulocyte-macrophage progenitors is increased in obese Zucker and non-obese but insulin resistant Goto-Kakizaki rats. Eur J Pharmacol 696:172–178

    Article  PubMed  Google Scholar 

  16. Benkő I, Djazayeri K, Abrahám C, Zsuga J, Szilvássy Z (2003) Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil. Eur J Pharmacol 477:179–182

    Article  PubMed  Google Scholar 

  17. Djazayeri K, Szilvássy Z, Peitl B, Németh J, Nagy L, Kiss A, Szabó B, Benkő I (2005) Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment. Eur J Pharmacol 522:122–129

    Article  CAS  PubMed  Google Scholar 

  18. Djazayeri K, Szilvássy Z, Benkő K, Rózsa B, Szabó B, Szentmiklósi AJ, Benkő I (2006) Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil. Pharmacol Res 53:156–161

    Article  CAS  PubMed  Google Scholar 

  19. Kemény-Beke A, Berényi E, Facskó A, Damjanovich J, Horváth A, Bodnár A, Berta A, Aradi J (2006) Antiproliferative effect of 4-thiouridylate on OCM-1 uveal melanoma cells. Eur J Ophthalmol 16:680–685

    PubMed  Google Scholar 

  20. Benkő I, Hernádi F, Megyeri A, Kiss A, Somogyi G, Tegyey Z, Kraicsovits F, Kovács P (1999) Comparison of the toxicity of fluconazole and other azole antifungal drugs to murine and human granulocyte-macrophage progenitor cells in vitro. J Antimicrob Chemother 43:675–681

    Article  PubMed  Google Scholar 

  21. Berényi E, Benkő I, Vámosi G, Géresi K, Tárkányi I, Szegedi I, Lukács L, Juhász I, Kiss C, Fésüs L, Aradi J (2011) In vitro and in vivo activity of 4-thio-uridylate against JY cells, a model for human acute lymphoid leukemia. Biochem Biophys Res Commun 410:682–687

    Article  PubMed  Google Scholar 

  22. Oikawa A, Siragusa M, Quaini F, Mangialardi G, Katare RG, Caporali A, van Buul JD, van Alphen FP, Graiani G, Spinetti G, Kraenkel N, Prezioso L, Emanueli C, Madeddu P (2010) Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 30:498–508

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Ferraro F, Lymperi S, Méndez-Ferrer S, Saez B, Spencer JA, Yeap BY, Masselli E, Graiani G, Prezioso L, Rizzini EL, Mangoni M, Rizzoli V, Sykes SM, Lin CP, Frenette PS, Quaini F, Scadden DT (2011) Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 3:104ra101. doi:10.1126/scitranslmed.3002191

    PubMed Central  PubMed  Google Scholar 

  24. DiPersio JF (2011) Diabetic stem-cell “mobilopathy”. N Engl J Med 365:2536–2538

    Article  CAS  PubMed  Google Scholar 

  25. Gilbert RE (2013) Augmenting endothelial repair in diabetes: role of bone marrow-derived cells. Can J Diabetes 37:315–318

    Article  PubMed  Google Scholar 

  26. Wan J, Xia L, Liang W, Liu Y, Cai Q (2013) Transplantation of bone marrow-derived mesenchymal stem cells promotes delayed wound healing in diabetic rats. J Diabetes Res. doi:10.1155/2013/647107

    Google Scholar 

  27. Shin L, Peterson DA (2012) Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Transl Med 1:125–135

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E 3rd (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia group B. J Natl Cancer Inst 90:1205–1211

    Article  CAS  PubMed  Google Scholar 

  29. Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lindtner J, Collins J, Gelber RD, Thürlimann B, Rudenstam CM (1998) Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 34:1693–1700

    Article  CAS  PubMed  Google Scholar 

  30. Morrow T, Siegel M, Boone S, Lawless G, Carter W (2002) Chemotherapy dose intensity determination as a quality of care measure for managed care organizations in the treatment of early-stage breast cancer. Am J Med Qual 17:218–224

    Article  PubMed  Google Scholar 

  31. Griggs JJ, Sorbero ME, Lyman GH (2005) Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165:1267–1273

    Article  PubMed  Google Scholar 

  32. Canal P, Chatelut E, Guichard S (1998) Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 56:1019–1038 Review

    Article  CAS  PubMed  Google Scholar 

  33. Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O’Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB 3rd, Fuchs CS (2004) Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 22:648–657

    Article  PubMed  Google Scholar 

  34. Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104–110

    Article  CAS  PubMed  Google Scholar 

  35. Yancik R, Ganz PA, Varricchio CG, Conley B (2001) Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 19:1147–1151

    CAS  PubMed  Google Scholar 

  36. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH (2009) Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 27:2170–2176

    Article  PubMed Central  PubMed  Google Scholar 

  37. Umemoto Y, Tsuji K, Yang FC, Ebihara Y, Kaneko A, Furukawa S, Nakahata T (1997) Leptin stimulates the proliferation of murine myelocytic and primitive hematopoietic progenitor cells. Blood 90:3438–3443

    CAS  PubMed  Google Scholar 

  38. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzario DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molino AA, Kurshan N, Mejia W, Santopietro S, Yakar S, Wood TL, LeRoith D (2010) Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70:741–751

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238–10246

    Article  CAS  PubMed  Google Scholar 

  40. Belfiore A, Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18:R125–R147

    Article  CAS  PubMed  Google Scholar 

  41. Beck Z, Kis A, Berényi E, Kovács P, Fésüs L, Aradi J (2009) 4-Thio-uridylate (UD29) interferes with the function of protein-SH and inhibits HIV replication in vitro. Pharmacol Rep 61:343–347

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the common fund of European Union and Hungarian government (TÁMOP-4.1.1.F-13/1-2013-0004).

Conflict of interest

All authors declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Nagyerdei blv. 98, Debrecen, 4032, Hungary

    Krisztina Géresi, Attila Megyeri, József Németh & Ilona Benkő

  2. Heart and Vascular Center, Semmelweis University, Gaál József 9-11, Budapest, 1122, Hungary

    Boglárka Szabó

  3. Department of Mathematics and Statistics, CFP AG, Seestrasse 25, 8702, Zollikon, ZH, Switzerland

    Zsolt Szabó

  4. Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Nagyerdei blv. 98, Debrecen, 4032, Hungary

    János Aradi

Authors
  1. Krisztina Géresi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Attila Megyeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boglárka Szabó
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zsolt Szabó
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. János Aradi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. József Németh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ilona Benkő
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ilona Benkő.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Géresi, K., Megyeri, A., Szabó, B. et al. Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus. Cancer Chemother Pharmacol 75, 609–618 (2015). https://doi.org/10.1007/s00280-015-2679-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2679-x

Keywords

Search

Navigation